Press Releases Interpace Biosciences, Inc.

Equities

IDXG

US46062X3035

Market Closed - OTC Markets Other stock markets 18:21:55 10/05/2024 BST			5-day change	1st Jan Change
1.45 ^USD	+3.57%		+2.84%	+34.26%

05-09	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-07	Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Interpace Biosciences Announces First Quarter 2024 Financial and Business Results	05-09	AQ
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results	03-07	AQ
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results	11-08	AQ
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results	09/08/23	AQ
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement	10/07/23	AQ
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05/06/23	AQ
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results	12/05/23	AQ
INTERPACE BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	25/04/23	AQ
INTERPACE BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	27/03/23	AQ
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results	27/03/23	AQ
INTERPACE BIOSCIENCES, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	15/11/22	AQ
INTERPACE BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14/11/22	AQ
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern	14/11/22	GL
INTERPACE BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	04/11/22	AQ
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting	20/10/22	GL
INTERPACE BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	04/10/22	AQ
INTERPACE BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	07/09/22	AQ
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved	01/09/22	AQ
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.	31/08/22	AQ
Interpace Biosciences : Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved - Form 8-K	15/08/22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Interpace Biosciences, Inc.

Equities

IDXG

US46062X3035

Press Releases

Filters